Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Commercial Biosimilars

Zydus Looks To NASH Trials In Turkey, gVascepa Launch In The US

Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter

Commercial Clinical Trials

Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China

Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.

Commercial Deals

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.

Business Strategies Commercial

Poxel Looks To More Twymeeg Partnerships In Asia To Pay Off Debt

The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.

Sales & Earnings Deals

Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'

Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.

Commercial Sales & Earnings

The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma’s Past CEOs

As big pharma braces for a new wave of patent expiries, we speak to two former industry chiefs – Novartis’s Joe Jimenez and Schering-Plough’s Fred Hassan – about the approach they took in similar circumstances.

Strategy Sales & Earnings

Stock Watch: Pfizer Gets Back To Business As Usual

Sales Of Pfizer’s pandemic products decline as other vaccines are scheduled for a second-half launch but the road back to 2022’s all-time high in annual revenues will not be easy.

Stock Watch Sales & Earnings

Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August

Lupin has pushed the launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables

Commercial Sales & Earnings

Record Revenues For Takeda But Headwinds Coming

While Japan's largest pharma company reached a number of milestones last fiscal year, it is facing a number of challenges to revenues in 2023, for which it is looking to its core commercial portfolio and pipeline to help drive growth.

Business Strategies Commercial

Merck KGaA Could Benefit From Bavencio Sales Growth Until 2024

While Q1 earnings were nothing exciting, the German major highlighted that Pfizer’s decisions to return to the rights to Bavencio would boost performance in the near term, although competition from Seagen is on the horizon.

Sales & Earnings Companies

Xarelto Declines Are New Normal At Bayer

Sales of the blockbuster Factor Xa blood thinner Xarelto declined more steeply than was expected but Bayer’s second biggest seller Eylea is still performing well.

Sales & Earnings Business Strategies
UsernamePublicRestriction

Register